Author(s)
Faraz Wasim , MAMEDOV UMID SUNNATOVICH
- Manuscript ID: 140384
- Volume: 2
- Issue: 6
- Pages: 663–670
Subject Area: Other
Abstract
Glioblastoma GBM remains one of oncology's most formidable challenges with median survival stagnating at 12 to 15 months despite aggressive treatment. This prospective phase I and II trial evaluated a novel four pronged therapeutic approach in 23 patients with recurrent IDH wild type GBM.
1. Real time intraoperative mass spectrometry iknife for precision tumor resection
2. CRISPR engineered NKG2D CAR NK cells with PD 1 knock out
3. Personalized oncolytic adenovirus Delta 24 RGD IL12
4. Metabolic preconditioning using a ketogenic diet with dichloroacetate DC and metformin
Results demonstrated a median progression-free survival of 9.8 months 95% CI 7.4 12.1 versus 4.2 months historically p<0.001 with 62% 12 month overall survival. Three patients (13%) achieved complete radiographic responses while cognitive function was preserved mean MMSE 28.1 post-treatment. This first in human protocol represents a significant advancement in GBM treatment warranting phase III evaluation.